Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 107,978

Document Document Title
WO/2018/005780A1
Provided herein is a drug delivery device and composition, such as a particle, comprising conditioned medium. Also provided herein is a method of preparing polymeric particles for release of conditioned medium. Further, a tissue growth s...  
WO/2018/003452A1
This kidney production method comprises: a step for tissue-specific removal of the metanephric mesenchyme of the metanephros of a non-human animal; a step of transplanting, in the metanephros, kidney precursor cells of non-human animal o...  
WO/2018/004253A2
The present invention relates to a bioprobe for detecting a target protein, comprising an aptamer which specifically binds to the target protein, and an immune cell linked to the aptamer via a linker, and provides a bioprobe that is capa...  
WO/2018/005477A1
A method of making a spheroid is provided that includes the step of providing a suspension having one or more biologically-relevant materials dispersed within a biocompatible medium. An amount of a hydrophilic material is deposited on a ...  
WO/2018/005378A1
The present invention provides an invasive cancer stem cell (iCSC) or a substantively homogeneous cell population including said iCSC based on a cell-surface marker. The present invention further provides an invasive leukemia stem cell (...  
WO/2018/005546A1
The present disclosure provides the development of engineered cardiomyocytes having mutations in transcription factor involved in vivo with cardiac development and/or function. These cell populations comprise mutations that are associate...  
WO/2018/006037A1
The present invention provides, in some embodiments, multi-layer silk compositions including a first layer comprising silk fibroin and keratinocytes, a second layer comprising silk fibroin and fibroblasts, a third layer comprising silk f...  
WO/2018/003476A1
The present invention provides a cell-suspension membrane separation method with which cells and debris can be properly separated, and a cell culture device. More specifically, membrane separation treatment of a cell suspension is perfor...  
WO/2018/003339A1
Provided is a method for controlling the activity of a nuclease in response to a cell-specific miRNA, said method comprising linking a nucleic acid sequence specifically recognized by the miRNA to a nucleic acid sequence encoding the nuc...  
WO/2018/002358A1
The present invention generally relates to T-cells, such as CD8+ T-cells, CD4+ T-cells, CD3+ T-cells, γδ T-cells or natural killer (NK) T-cells, transfected / transduced with a fusion protein which is recruited by the use of trivalent,...  
WO/2018/005556A1
Provided are methods of identifying peptide epitopes of an antigen recognized by the non-classical major histocompatibility complex (MHC) molecule designated MHC-E. In some embodiments, the antigen is a tumor antigen, autoimmune antigen ...  
WO/2018/000089A1
Polynucleotides and polypeptides useful in the manufacture of a class of chemical compounds known as alkaloids are provided. The polynucleotides and polypeptides may be used to synthesize alkaloids, including reticuline, thebaine and mor...  
WO/2018/003450A1
This organ production method comprises: a step for tissue-specific removal of a first portion of an organ of a non-human animal partway through the generation thereof; a step for transplanting, into the area from which the first portion ...  
WO/2018/000288A1
Provided is a method for inducing a pluripotent stem cell in a three-dimensional reprogramming system using a combination of reprogramming factors. The method uses a collagen frame and calcium phosphate nanoparticle as a genetic vector t...  
WO/2018/002924A1
A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease acti...  
WO/2018/005640A1
This disclosure provides miRNA/mRNA pairs that can be used to increase the efficacy of T cells or to down-modulate T cell efficacy and restore equilibrium.  
WO/2018/000105A1
The present invention relates to the field of genetic engineering, preferably the expression of recombinant proteins (RP). In particular, the invention relates to a promoter and variants thereof having an equal function and more than 90%...  
WO/2018/001874A1
The invention provides a fusion protein for use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host´s immune response directed against the transplant. The fusion protein is adapted ...  
WO/2018/000657A1
A method for constructing a cell model for detecting a pyrogen, a cell model and a pyrogen detection kit. CRISPR/CAS9 is used to induce double bond breaks to form at specific positions of a genome, a homologous recombination is used to r...  
WO/2018/003451A1
This kidney production method comprises: a step for tissue-specific removal of the metanephric mesenchyme of the metanephros of a non-human animal; a step for transplanting human kidney precursor cells into the metanephros; and a step of...  
WO/2018/005712A1
The invention relates to compositions comprising a heterogeneous population of T cells with reactivity to selected antigens that are useful for adoptive immunotherapy and methods for making the T cell compositions.  
WO/2018/002290A1
The present invention provides an in vitromethod for obtaining cells of the pancreatic endocrine lineage, comprising a step of culturing pancreatic progenitor cells, wherein said pancreatic progenitor cells are in a cell culture medium c...  
WO/2018/005975A1
Provided herein are methods and compositions for a suicide gene approach comprising an expression vector comprising a cell cycle-dependent promoter driving the expression of a suicide gene. Also provided herein are methods to render prol...  
WO/2018/006067A1
Compositions for the treatment or prevention of multiple sclerosis are provided. In some embodiments, the composition comprises an isolated peptide comprising a partial amino acid sequence of a myelin oligodendrocyte glycoprotein (MOG) p...  
WO/2018/002036A1
The present invention is directed to a cell culture obtainable from CHO DG44 cells which are capable of being cultured under serum-free or protein-free culture conditions, and which express a biosimilar antibody for the monoclonal antibo...  
WO/2018/005413A1
A method, a computer readable medium, and a system for cell annotation are disclosed. The method includes receiving at least one new cell image for cell detection; extracting cell features from the at least one new cell image; comparing ...  
WO/2018/002378A1
The present invention relates to genetically modified HepaRG cells as deposited on 10-5-2016 at the Leibniz-lnstitut DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, under No. DSM ACC3291. The invention further relates t...  
WO/2018/003779A1
Provided are a mRNA that forcibly expresses a protein gene in response to a miRNA, and a method for forcibly expressing the same. This artificial mRNA comprises: a sequence that encodes a protein gene; a miRNA target sequence connected t...  
WO/2018/002940A1
The invention relates to platform for of the preparation of improved nucleic acid delivery vehicles, specifically, vehicles having an extended host recognition ability. The invention further provides improved vehicles, compositions and u...  
WO/2017/223241A1
Disclosed herein are methods of reprograming autologous tissues or cells into astrocytes or astroglial progenitor cells using one or more small molecule compounds only without any transgenes. Also disclosed are methods of preventing or t...  
WO/2017/223457A1
A population of Brown adipose tissue (BAT) cells generated from embryonic stem cells (ES) or induced pluripotent stem cells (iPS), called iBAT, the use thereof, methods to obtain iBAT by directed differentiation of ES/iPS, and media comp...  
WO/2017/219528A1
Provided is a preparation method for CD70-containing chimeric antigen receptor-modified T cells specifically recognizing EGFRvIII, comprising the following steps: A, plasmid construction, amplification and purification; B, lentivirus pac...  
WO/2017/219232A1
Provided is a cell reprogramming method based on a three-dimensional system. Cationic Pleurotus eryngii polysaccharide D-Sp, calcium phosphate and four plasmids encoding the Yamanaka factors are used as raw materials. Polysaccharide-calc...  
WO/2017/222593A1
The present disclosure relates to compositions and methods relating to chimeric antigen receptor (CAR) polypeptides and methods relating thereto. In one embodiment, the present disclosure relates to engineered cells having chimeric antig...  
WO/2017/222065A1
Provided is a three-dimensionally cultured skin sheet having a certain thickness. The present invention provides: a three-dimensionally cultured skin sheet at least includes epidermal cells, and has recesses and protrusions in at least a...  
WO/2017/219150A1
The present invention describes a method for treating cancer comprising adoptive transfer of tumor antigen specific CD8+ T cells and an oncolytic virus vaccine targeting the same antigen.  
WO/2017/223340A1
The present invention relates to methods of enhancing stem cell transplantation by treating pre-graft cells with silencing constructs for reducing expression of GASP (G-protein coupled receptor Associated Sorting Proteins) family genes, ...  
WO/2017/221873A1
The present invention provides a mutant coleoptera luciferase, which has a mutation of, in the amino acid sequence of wild type North America firefly luciferase among amino acid sequences encoding wild type coleoptera luciferases, substi...  
WO/2017/219934A1
Provided is a transgenic killer cell. A genome of the transgenic killer cell stably integrates a coding sequence comprising an antibody of a human Fc section, or an expression cassette of a coding sequence comprising a chimeric antigen r...  
WO/2017/220704A1
The invention relates to a composition comprising regulatory T (Treg) cells or effector T cells (Teff) which stably express an interleukin selected from the group consisting of interleukin-2 (IL-2) or interleukin-15 (IL-15).  
WO/2017/223330A1
The present disclosure relates to viral delivery of RNA utilizing self-cleaving ribozymes and applications of such, including but not limited to CRISPR-Cas related applications.  
WO/2017/221870A1
[Problem] The present invention addresses the problem of providing an artificial skin having hair follicles, sebaceous glands, and pores. [Solution] Provided is a method for producing an artificial skin that has hair follicles, sebaceous...  
WO/2017/223052A1
Compositions and methods are provided for biologically relevant in vitro screening of neural function, including determination of the effects of an agent on neural cells. The compositions of the invention useful in such screening methods...  
WO/2017/223494A1
Disclosed are compositions comprising a non-homogenized chorionic matrix, a homogenized amniotic matrix and a homogenized UC (UC) matrix, wherein the non- homogenized chorionic matrix comprises viable cells. Disclosed are methods of maki...  
WO/2017/223495A1
Contact of endothelial cells with inhibitors of inhibin and/or the alpha subunit of inhibin can be utilized to modify the activity of endothelial cell expression products including SMAD 1/5. Methods can also include inhibiting Alk1 and/o...  
WO/2017/219937A1
A CAR-T cell for efficiently and stably expressing an inhibiting antibody and an application thereof, and specifically, a transgenic T cell. A genome of the T cell stably integrates expression cassettes comprising nucleotide sequences of...  
WO/2017/219936A1
Provided is a transgenic T cell. A genome of the transgenic T cell stably integrates an expression cassette of a nucleic acid sequence comprising a code chimeric antigen receptor, an immune co-stimulatory molecule or an activated antibod...  
WO/2017/223569A1
The present invention provides for a composition comprising: (a) a first host cell capable of producing L-DOPA; and (b) a modified host cell is capable of converting L-DOPA into hydroxytyrosol (HTy); wherein any one or both of the first ...  
WO/2017/221075A1
The present application provided defective bovine adenovirus (BAV) vectors that lack pV function. Cell lines and methods of preparing such vectors are provided. In addition, the invention provides methods of treating a disease or disorde...  
WO/2017/222879A1
The invention provides for methods of differentiating pancreatic endocrine cells into pancreatic beta cells expressing PDX1, NKX6.1, MAFA, UCN3 and SLC2A. These pancreatic beta cells may be obtained by step-wise differentiation of plurip...  

Matches 1 - 50 out of 107,978